Adavosertib (MK-1775) - Moligand™, 10mM in DMSO , Serine/threonine-protein kinase WEE1 inhibitor, CAS No.955365-80-7, Serine/threonine-protein kinase WEE1 inhibitor

CAS: 955365-80-7 Cat. No.: A408386 Summenformel: C27H32N8O2 Molekulargewicht: 500.61 EG-Nummer: 680-342-0
Zu bestellen verfügbar
QUALITÄT & REINHEIT Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Synonyms
AZD1775|2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1ml
A408386-1ml
—
1 Auf Lager

196,89€

286,27€
Speichern 89,38 € (31.22%)
Enter a quantity for the sizes you want to add.

Übersicht

Information

Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
In vitro

MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells.

In vivo

MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models is also moderate.
Cell Data

cell lines:

Concentrations:Dissolved in DMSO, final concentrations ~10 μM

Incubation Time:24 hours

Powder Purity:≥98%

Spezifikationen

Synonyme
AZD1775 | 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one
Spezifikationen & Reinheit
Moligand™, 10mM in DMSO
Biochemische und physiologische Mechanismen
Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Storage
Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Note
Moligand™
Aktionsart
INHIBITOR
Mechanismus der Wirkung
Serine/threonine-protein kinase WEE1 inhibitor
Produkteigenschaften
ALogP
3.1
Namen und Kennungen
Isomere SMILES
CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O
Molekulargewicht
500.61
Reaxys
12993372
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12993372&ln=

Erweiterte Daten

Zugehörige Ziele (menschlich)
JAK3 Tclin Tyrosine-protein kinase JAK3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PLK1 Tchem Serine/threonine-protein kinase PLK1 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
WEE1 Tchem Wee1-like protein kinase (7 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
WEE2 Tchem Wee1-like protein kinase 2 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADK Tchem Adenosine kinase (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot NumberCertificate TypeDatumArtikel
L2214613L2214613Certificate of AnalysisJul 03, 2026 A408386
Sicherheit und Gefahren (GHS)
Piktogramm(e)
Signal
Warning
Gefahrenhinweise

H227:Combustible liquid

Sicherheitshinweise

P210:Keep away from heat, hot surface, sparks, open flames and other ignition sources. - No smoking.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P370+P378:In case of fire: Use ... to extinguish.

P403+P235:Store in a well-ventilated place. Keep cool.

P501:Dispose of contents/container to an approved waste disposal plant.

Reaxys
12993372
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12993372&ln=
FAQs und Artikel
Lösungsrechner
Bewertungen

Kundenbewertungen

Benötigen Sie Hilfe bei der Auswahl der Qualität?

Unser Leitfaden zur Qualitätsauswahl behandelt Reinheit, Stabilisatorstatus und Anwendungseignung für alle Varianten in unserem Katalog.

Moligand™ Qualitätsleitfaden ansehen →

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.